Srinika Ranasinghe
Associate Director, Center for Immuno-oncology (CIO) @Dana-Farber Cancer Institute
Signup · Get unlimited contacts
WORK HISTORY
Associate Director, Center for Immuno-oncology (CIO) @Dana-Farber Cancer Institute
Boston, MA, US
The Center for Immuno-Oncology (CIO) at the Dana-Farber serves as a central hub for conducting first-in-human phase I clinical trials of immunotherapy across a variety of solid tumors. The vision of the CIO is to facilitate the development of novel immunotherapy treatments - with academic and industry partners - that will improve the outcomes of patients with cancer: • Collaborate on PI-initiated or industry-sponsored IO trials• Clinical trial design and conduct• Clinical care delivery to patients• Banking specimens (tissue, whole blood, PBMC, serum, plasma, saliva, urine, stool)• Biomarker and immune correlates analysis > Blood and fresh biopsies (FACS, CyTOF, Luminex, TCR Seq) http://ciolab.dfci.harvard.edu/> FFPE Tissue (IHC, multiplex IF, FISH, Nanostring) http://ciopath.dfci.harvard.edu/• Bio-statistical analyses of response, resistance, toxicity• CIO is part of the NIH-NCI Cancer Immunotherapy Trials Network, CIMACS, and CIDC• Director Stephen Hodi, M.D, is a world leader in the clinical development of checkpoint inhibitors (FDA approval of Ipilimumab) and combination therapiesAssociate Director, Srin Ranasinghe, Ph.D, is responsible for overall CIO research operations and will prioritize, plan, and coordinate projects/trials with academic and industry partners.
EDUCATION
University of Oxford
Bachelor's degree, Biological Sciences
University of Oxford
Doctor of Philosophy (PhD), Immunology
SKILLS
ABOUT SRINIKA RANASINGHE
Associate Director, Center for Immuno-Oncology (CIO) at Dana-Farber Cancer Institute
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.